Episode 9- Brad Hartman- Chief People Officer
Joining us on our latest episode of "The Biotech Project" is Chief People Officer, Brad Hartman. Brad shares his story of development into the people leader his is today as well as a robust discussion on how to position yourself and an organization to d...
Joining us on our latest episode of "The Biotech Project" is Chief People Officer, Brad Hartman. Brad shares his story of development into the people leader his is today as well as a robust discussion on how to position yourself and an organization to develop and achieve at new levels. Listen in as Brad discusses his approach on organization wide development and recognition as well as his passion for diversity and inclusion.
Visit us at www.thebiotechproject.com for Brad's biography!
Brad Hartman
Chief People Officer
Brad is a purpose-driven biotech executive & entrepreneur who is deeply committed to unlocking the potential in individuals, teams, and the company to radically improve patients' lives. He passionately believes in the power of culture to elevate organizational performance and capability through innovative People practices and a more humanistic, caring approach.
Brad has spent the past 15 years building teams & culture at biotech companies from early research stages through commercialization. He has deep cell and gene therapy experience from Unum Therapeutics (CAR-T) as well as FerGene (gene therapy), where he recently served as the Chief People Officer. Brad has played a significant role in launching multiple innovative therapies, including Kalydeco® (cystic fibrosis), Kalbitor® (hereditary angioedema), and Incivek® (hepatitis C), which was one of the fastest blockbuster drug launches of all time. Brad also founded and built out his own Executive Search firm, ConnectedSearch, into a leading life science search practice.
Brad received his BS in Neuroscience from the University of Rochester and worked at both the National Cancer Institute and the Graduate School of Pharmacology at the University of Rochester in cellular pharmacology.